BR0109779A - Soluções moleculares hidrofìlicas dispersas de carvedilol - Google Patents

Soluções moleculares hidrofìlicas dispersas de carvedilol

Info

Publication number
BR0109779A
BR0109779A BR0109779-2A BR0109779A BR0109779A BR 0109779 A BR0109779 A BR 0109779A BR 0109779 A BR0109779 A BR 0109779A BR 0109779 A BR0109779 A BR 0109779A
Authority
BR
Brazil
Prior art keywords
carvedilol
molecular solutions
dispersed molecular
hydrophilic dispersed
pharmaceutically acceptable
Prior art date
Application number
BR0109779-2A
Other languages
English (en)
Inventor
Rolf-Dieter Gabel
Alexander Wirl
Walter Preis
Guenter Neugebauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0109779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0109779A publication Critical patent/BR0109779A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"SOLUçõES MOLECULARES HIDROFìLICAS DISPERSAS DE CARVEDILOL". A presente invenção refere-se a composições farmaceuticamente aceitáveis que compreendem carvedilol ou um sal farmaceuticamente aceitável do mesmo, distribuídas como uma dispersão molecular em uma concentração acima de 5% (p/p), bem como formas farmacêuticas de administração que compreendem tais composições e seu uso para o tratamento e/ou profilaxia de doenças tais como hipertensão, insuficiência cardíaca ou angina do peito.
BR0109779-2A 2000-04-03 2001-03-28 Soluções moleculares hidrofìlicas dispersas de carvedilol BR0109779A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107093 2000-04-03
PCT/EP2001/003502 WO2001074357A1 (en) 2000-04-03 2001-03-28 Hydrophilic molecular disperse solutions of carvedilol

Publications (1)

Publication Number Publication Date
BR0109779A true BR0109779A (pt) 2003-01-21

Family

ID=8168348

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109779-2A BR0109779A (pt) 2000-04-03 2001-03-28 Soluções moleculares hidrofìlicas dispersas de carvedilol

Country Status (24)

Country Link
US (3) US20010036959A1 (pt)
EP (1) EP1272179B1 (pt)
JP (1) JP2003528915A (pt)
KR (1) KR100478793B1 (pt)
CN (1) CN1189171C (pt)
AR (1) AR029825A1 (pt)
AT (1) ATE450257T1 (pt)
AU (2) AU2001256227B2 (pt)
BR (1) BR0109779A (pt)
CA (1) CA2401910C (pt)
CZ (1) CZ20023625A3 (pt)
DE (1) DE60140662D1 (pt)
HR (1) HRP20020777A2 (pt)
HU (1) HUP0300342A3 (pt)
IL (1) IL151642A0 (pt)
MA (1) MA26888A1 (pt)
MX (1) MXPA02009725A (pt)
NO (1) NO20024733L (pt)
NZ (1) NZ521232A (pt)
PL (1) PL358103A1 (pt)
RU (1) RU2248204C2 (pt)
WO (1) WO2001074357A1 (pt)
YU (1) YU72602A (pt)
ZA (1) ZA200207304B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067910B1 (en) * 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
US20050019399A1 (en) * 2001-09-21 2005-01-27 Gina Fischer Controlled release solid dispersions
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
DE60221683T2 (de) * 2001-09-28 2008-04-30 F. Hoffmann-La Roche Ag Pseudopolymorphe formen von carvedilol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EP1501500A2 (en) * 2002-05-03 2005-02-02 SmithKline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
EP1539140A4 (en) * 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
WO2004002419A2 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2360102T3 (es) * 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
CN1819817A (zh) * 2003-07-09 2006-08-16 株式会社钟根堂 一种泰克利玛的固体分散体
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
PT1663216E (pt) * 2003-08-29 2012-02-14 Veloxis Pharmaceuticals As Dispersões sólidas que compreendem tacrolímus
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
BRPI0418294A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080138404A1 (en) * 2006-12-06 2008-06-12 Biovail Laboratories International S.R.L. Extended release formulations of carvedilol
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
ATE539769T1 (de) 2008-03-04 2012-01-15 Lupin Ltd Stabile pharmazeutische zusammensetzungen mit carvedilol
ES2330404B1 (es) * 2008-05-19 2010-09-22 Universidad De Barcelona Solucion acuosa para la preservacion de tejidos y organos.
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
WO2011154009A1 (en) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprising an active principle in an amorphous form and a porous adsorbent material
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
DE69826113T2 (de) * 1997-03-11 2005-01-20 Arakis Ltd., Saffron Walden R- und s- enantiomere getrennteteile enthaltende dosierungsformen
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19816036A1 (de) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
US6852337B2 (en) * 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
US6664284B2 (en) * 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6710184B2 (en) * 2002-01-15 2004-03-23 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation

Also Published As

Publication number Publication date
HUP0300342A2 (hu) 2003-06-28
ATE450257T1 (de) 2009-12-15
AR029825A1 (es) 2003-07-16
AU2001256227B2 (en) 2005-09-01
NO20024733D0 (no) 2002-10-02
KR100478793B1 (ko) 2005-03-24
RU2002129571A (ru) 2004-03-27
DE60140662D1 (de) 2010-01-14
MA26888A1 (fr) 2004-12-20
NO20024733L (no) 2002-10-02
CA2401910A1 (en) 2001-10-11
ZA200207304B (en) 2003-12-11
PL358103A1 (en) 2004-08-09
CN1189171C (zh) 2005-02-16
CA2401910C (en) 2008-04-15
HRP20020777A2 (en) 2004-12-31
NZ521232A (en) 2004-05-28
KR20030019339A (ko) 2003-03-06
US20010036959A1 (en) 2001-11-01
US20030004205A1 (en) 2003-01-02
CZ20023625A3 (cs) 2003-04-16
US20050271721A1 (en) 2005-12-08
MXPA02009725A (es) 2003-03-27
RU2248204C2 (ru) 2005-03-20
WO2001074357A1 (en) 2001-10-11
CN1420771A (zh) 2003-05-28
HUP0300342A3 (en) 2005-07-28
YU72602A (sh) 2005-03-15
AU5622701A (en) 2001-10-15
JP2003528915A (ja) 2003-09-30
IL151642A0 (en) 2003-04-10
EP1272179A1 (en) 2003-01-08
EP1272179B1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
TR199903053T2 (xx) Benzimidazol t�revleri.
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BRPI0614197B8 (pt) composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
DE69803670T2 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
AR014082A1 (es) Concentrado oral de sertralina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA A INT. CL A61K 31/403; A61K 47/04, 47/34; A61K 9/14, 9/22; A61P 9/00, 9/04, 9/10, 9/12

Ipc: A61K 31/403 (2010.01), A61K 47/04 (2010.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.